Bristol-Myers Squibb Company shares are trading higher after the company announced the Lisocabtagene Maraleucel (Liso-Cel) met its primary and secondary endpoints in the TRANSCEND NHL 001 study at the ASH 2019.
Benzinga Newsdesk